
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HMBD-002
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Percheron Therapeutics
Deal Size : $290.0 million
Deal Type : Licensing Agreement
Hummingbird Licenses HMBD-002, an Anti-VISTA Monoclonal Antibody to Percheron Therapeutics
Details : Percheron gains an exclusive worldwide license to develop, manufacture, and commercialize HMBD-002, a monoclonal antibody therapy targeting VISTA, in all territories and indications.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
June 25, 2025
Lead Product(s) : HMBD-002
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Percheron Therapeutics
Deal Size : $290.0 million
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Recipient : Callio Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Callio Launches with $187M Series A to Advance ADC Clinical Development
Details : Callio has entered into an exclusive worldwide license agreement with Hummingbird Bioscience for its multi-payload ADC platform in oncology, and associated intellectual property and pipeline assets.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 03, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : Callio Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Hummingbird Bioscience Licenses Novel Antibodies to Immunome
Details : Under the terms of the license agreement, Immunome will be responsible for the research, development, manufacturing and commercialization of products incorporating these antibodies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 07, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HMBD-501
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Endeavor Biomedicines
Deal Size : $430.0 million
Deal Type : Licensing Agreement
Details : Under the agreement, Endeavor has acquired exclusive worldwide rights to Hummingbird Bio’s HMBD-501, a next-generation HER3-targeted antibody-drug conjugate (ADC).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 19, 2023
Lead Product(s) : HMBD-501
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Endeavor Biomedicines
Deal Size : $430.0 million
Deal Type : Licensing Agreement

Details : HMBD-001 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 26, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HMBD-001
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HMBD-001 is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 20, 2023
Lead Product(s) : HMBD-001
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HMBD-001,Cetuximab
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, Hummingbird will evaluate its potentially best-in-class HER3-targeting antibody, HMBD-001, in combination with SoC chemotherapy with or without Merck's cetuximab, anti-EGFR mAb, in patients with sqNSCLC in a Phase 1b clinical tri...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
May 15, 2023
Lead Product(s) : HMBD-001,Cetuximab
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HMBD-001
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : George Clinical
Deal Size : Undisclosed
Deal Type : Agreement
George Clinical to Support Hummingbird’s Phase 1 Oncology Trials
Details : George Clinical will provide its full-service CRO expertise for the Hummingbird sponsored trials, including HMBD-001, a unique antibody engineered to bind strongly and specifically to the dimerization interface of HER3, developed with its Rational Antibo...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
May 04, 2023
Lead Product(s) : HMBD-001
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : George Clinical
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HMBD-001
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HMBD-001 is an anti-HER3 antibody in development that has the potential to fully block both ligand-dependent and independent HER3 activation and oncogenic signaling, by targeting a key epitope located at the interface where HER3 forms heterodimers with H...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 06, 2023
Lead Product(s) : HMBD-001
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Preclinical
Recipient : Synaffix
Deal Size : $150.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Hummingbird Bio is granted rights to utilize Synaffix proprietary Antibody-Drug Conjugate (ADC) technologies GlycoConnect™ and HydraSpace™, in combination with select toxSYN™ linker-payloads.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 04, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Preclinical
Recipient : Synaffix
Deal Size : $150.0 million
Deal Type : Licensing Agreement
